Pfizer and Innovent Biologics escalated China-linked oncology dealmaking with a multi-drug collaboration spanning 12 early-stage and de novo antibody programs. Pfizer will pay Innovent $650 million upfront and up to $9.85 billion in milestones, with Innovent leading through Phase I and Pfizer taking over subsequent global development on selected programs. Separately, Pfizer also described a $10.5B, multi-drug R&D collaboration with the same Innovent platform focused on next-generation targeted cancer therapies, including antibody-drug conjugates (ADCs) and multispecific antibodies. The structure underscores how U.S. companies are building pipelines around China’s faster early-stage execution model, while shifting later global development responsibilities. The alliance intensifies competitive pressure across oncology modalities—particularly ADCs and multispecifics—while raising stakes for U.S. policy discussions about outbound investment and technology security.